Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC reduced its holdings in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) by 9.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,940 shares of the company’s stock after selling 2,300 shares during the period. Nisa Investment Advisors LLC’s holdings in Deciphera Pharmaceuticals were worth $370,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. Legal & General Group Plc increased its holdings in shares of Deciphera Pharmaceuticals by 4.2% in the fourth quarter. Legal & General Group Plc now owns 18,891 shares of the company’s stock valued at $310,000 after purchasing an additional 754 shares during the period. Dana Investment Advisors Inc. increased its holdings in shares of Deciphera Pharmaceuticals by 2.5% in the second quarter. Dana Investment Advisors Inc. now owns 35,316 shares of the company’s stock valued at $497,000 after purchasing an additional 870 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in shares of Deciphera Pharmaceuticals by 96.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 2,026 shares of the company’s stock valued at $26,000 after purchasing an additional 997 shares during the period. FMR LLC increased its holdings in shares of Deciphera Pharmaceuticals by 1.3% in the second quarter. FMR LLC now owns 87,638 shares of the company’s stock valued at $1,152,000 after purchasing an additional 1,102 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Deciphera Pharmaceuticals by 2.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 41,527 shares of the company’s stock valued at $670,000 after purchasing an additional 1,117 shares during the period. 70.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on DCPH shares. Stifel Nicolaus increased their price objective on Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the company a “buy” rating in a report on Wednesday, February 7th. JPMorgan Chase & Co. raised their target price on Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Wednesday, March 20th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $23.00.

Deciphera Pharmaceuticals Stock Down 3.3 %

Deciphera Pharmaceuticals stock opened at $14.23 on Friday. The firm has a market cap of $1.15 billion, a price-to-earnings ratio of -6.21 and a beta of 0.39. Deciphera Pharmaceuticals, Inc. has a 52 week low of $9.90 and a 52 week high of $17.73. The business’s 50-day moving average price is $15.70 and its 200 day moving average price is $14.21.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last issued its quarterly earnings results on Tuesday, February 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.04. The company had revenue of $48.30 million for the quarter, compared to the consensus estimate of $45.93 million. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. Deciphera Pharmaceuticals’s revenue for the quarter was up 32.9% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.60) earnings per share. Equities analysts expect that Deciphera Pharmaceuticals, Inc. will post -2.16 EPS for the current year.

Deciphera Pharmaceuticals Profile

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.